In parallel with mechanistic studies, transgenic mouse experiments have validated the SS18-SSX fusion as a putative oncogenic driver in synovial sarcoma (Haldar et al., 2007; Haldar et al., 2009; Jones et al., 2016; Benabdallah et al., 2023). Here, SSX2 is linked to synovial sarcoma.